Daewoong's NUCEIVA® Launches In Australia: A New Era In Beauty Begins

Daewoong Pharmaceutical has made a significant stride in its global journey with the official introduction of its botulinum toxin product, NUCEIVA®, to the Australian market. This milestone was celebrated on the 19th, following its debut at the “Aesthetics 2024” conference in Sydney, held from August 1 to 4.

The South Korean pharmaceutical company, recognized for its cutting-edge innovations, initially entered the U.S. market in 2019 after obtaining FDA approval for its botulinum toxin. Since then, NUCEIVA® has steadily expanded its reach across North America, South America, Europe, Asia, and now Oceania. Approval from the Australian Therapeutic Goods Administration (TGA) for NUCEIVA® 100 units was secured in January of last year, laying the groundwork for its regional launch.

Evolus, Daewoong's global partner, was instrumental in bringing NUCEIVA® to Australia. During the 'Aesthetics 2024' event, Evolus hosted a booth and organized a symposium attended by over 200 medical professionals, showcasing NUCEIVA® and its promising applications in the aesthetic field.

Dr. Steven Liu, a prominent plastic surgeon in Australia, shared his perspective on the increasing popularity of non-invasive treatments among the younger demographic. He said, "Interest in non-surgical procedures and aesthetics is increasing among the younger generation in Australia. NUCEIVA® is expected to provide a new option in the field of aesthetics to Australian medical professionals, enabling them to achieve optimal results that meet patient preferences and demands."

Daewoong Pharmaceutical's CEO, Park Sung-soo, highlighted the crucial role that the Australian market plays in the company's strategic plans, by saying “The entry into the Australian market will be an important momentum to enhance the global influence of Daewoong Pharmaceutical's botulinum toxin product," he stated. "We expect rapid growth in the Australian market through the excellent product quality of NUCEIVA® and Evolus's differentiated local marketing strategy focusing on the millennial generation."

Evolus aims to boost NUCEIVA®'s visibility by conducting local training sessions and seminars to inform medical professionals about the product’s uses and advantages. This strategy is designed to establish a solid market footprint and encourage widespread adoption among healthcare providers.